论文部分内容阅读
本文应用硫代巴比妥酸显色比色法和邻苯三酚自氧法测定８７例脑梗塞患者血清中ＬＰ０、ＳＯＤ含量，随机分组分别用巴曲酶和低分子右旋糖酐＋丹参治疗，并测定治疗后血清中ＬＰＯ、ＳＯＤ含量，研究证明脑梗塞患者血清中ＬＰＯ显著高于非脑血管病及健康对照者（Ｐ＜０．０１），而ＳＯＤ显著低于非脑血管病及健康对照者（Ｐ＜０．０１）。巴曲酶治疗后血清中ＬＰＯ明显低于治疗前（Ｐ＜０．０１），ＳＯＤ高于治疗前（Ｐ＜０．０５），而对照组无差异（Ｐ＞０．０５）。提示巴曲酶可抑制脑梗塞患者血清中ＬＰＯ产生，提高ＳＯＤ活性，具有保护神经细胞作用。
In this paper, thiobarbituric acid colorimetric assay and pyrogallol autoxidation method were used to determine the serum levels of LPO and SOD in 87 patients with cerebral infarction. The patients were randomly assigned to treatment with batroxobin and low molecular weight dextran plus salvia miltiorrhiza The levels of LPO and SOD in the serum after the treatment were measured. The results showed that the serum LPO in patients with cerebral infarction was significantly higher than those in non-cerebrovascular disease and healthy controls (P <0.01), and SOD was significantly lower than those in non-cerebrovascular disease and healthy controls (P <0.01). LPO in serum after treatment with batroxobin was significantly lower than that before treatment (P <0.01), and SOD was higher than before treatment (P <0.05), while no significant difference was found in the control group (P> 0.05). It is suggested that batroxobin can inhibit the production of LPO in the serum of patients with cerebral infarction, increase the activity of SOD and protect the neurons.